DK0561183T3 - Monoklonalt anti-gangliosid-antistof, fremstilling deraf og anvendelse deraf som tumorterapeutikum - Google Patents

Monoklonalt anti-gangliosid-antistof, fremstilling deraf og anvendelse deraf som tumorterapeutikum

Info

Publication number
DK0561183T3
DK0561183T3 DK93102895T DK93102895T DK0561183T3 DK 0561183 T3 DK0561183 T3 DK 0561183T3 DK 93102895 T DK93102895 T DK 93102895T DK 93102895 T DK93102895 T DK 93102895T DK 0561183 T3 DK0561183 T3 DK 0561183T3
Authority
DK
Denmark
Prior art keywords
preparation
monoclonal anti
tumor therapeutic
ganglioside antibody
gq1b
Prior art date
Application number
DK93102895T
Other languages
Danish (da)
English (en)
Inventor
Klaus Bosslet
Gerhard Seemann
Wolfgang Dippold
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Application granted granted Critical
Publication of DK0561183T3 publication Critical patent/DK0561183T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/08—Sphingolipids
    • G01N2405/10—Glycosphingolipids, e.g. cerebrosides, gangliosides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK93102895T 1992-03-19 1993-02-25 Monoklonalt anti-gangliosid-antistof, fremstilling deraf og anvendelse deraf som tumorterapeutikum DK0561183T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4208795A DE4208795A1 (de) 1992-03-19 1992-03-19 Monoklonaler anti-gangliosid-antikoerper, seine herstellung und verwendung als tumortherapeutikum

Publications (1)

Publication Number Publication Date
DK0561183T3 true DK0561183T3 (da) 1999-05-25

Family

ID=6454438

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93102895T DK0561183T3 (da) 1992-03-19 1993-02-25 Monoklonalt anti-gangliosid-antistof, fremstilling deraf og anvendelse deraf som tumorterapeutikum

Country Status (12)

Country Link
US (1) US5730981A (no)
EP (1) EP0561183B1 (no)
JP (1) JP3513173B2 (no)
KR (1) KR100280948B1 (no)
AT (1) ATE169962T1 (no)
AU (1) AU666707B2 (no)
CA (1) CA2091967C (no)
DE (2) DE4208795A1 (no)
DK (1) DK0561183T3 (no)
ES (1) ES2121881T3 (no)
IL (1) IL105081A (no)
NO (1) NO315089B1 (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE388167T1 (de) 1999-09-30 2008-03-15 Kyowa Hakko Kogyo Kk Menschlicher antikörper gegen gangliosid gd3 für die transplantationskomplementarität bestimmente regionund derivate des antikörpers gegen das gangliosid gd3
JP2004531469A (ja) * 2000-12-08 2004-10-14 チルドレンズ メモリアル ホスピタル 皮膚疾病の治療に使用するガングリオシドを含む組成物
KR100517613B1 (ko) * 2003-03-31 2005-09-28 엘지전자 주식회사 증기분사식 드럼세탁기
EP1684076B1 (en) 2003-10-29 2008-12-31 Kumamoto Technology & Industry Foundation Diagnostic method for malignant melanoma
FI20070853A0 (fi) * 2007-11-09 2007-11-09 Glykos Finland Oy Glykaania sitovat monoklonaaliset vasta-aineet
US10752670B2 (en) * 2015-05-20 2020-08-25 Cellectis Anti-GD3 specific chimeric antigen receptors for cancer immunotherapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614610A (en) * 1984-12-21 1997-03-25 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
CA1339798C (en) * 1985-02-01 1998-04-07 Alan N. Houghton Method for treatment of neuroectodermal malignancies and epithelial carcinomas in humans
US5055559A (en) * 1986-02-20 1991-10-08 Oncogen Anti-melanoma antibody MG-21 for diagnosis and therapy of human tumors
EP0234122A3 (en) * 1986-02-21 1989-03-22 Oncogen Limited Partnership Tumor therapy with biologically active anti-tumor antibodies
US4849509A (en) * 1987-02-20 1989-07-18 The Wistar Institute Monoclonal antibodies against melanoma-associated antigens and hybrid cell lines producing these antibodies
JP2754206B2 (ja) * 1987-11-17 1998-05-20 メクト株式会社 α２→３結合を認識するモノクローナル抗体
JP2789469B2 (ja) * 1988-07-16 1998-08-20 メクト株式会社 ガングリオシドＧＱ▲下１▼▲下ｂ▼およびＧＴ▲下１▼▲下ａ▼を認識するモノクローナル抗体
EP0460607A3 (en) * 1990-06-05 1992-04-01 Bristol-Myers Squibb Company Novel monoclonal antibody to novel antigen associated with human tumors
DE4107154A1 (de) * 1990-10-11 1992-04-16 Boehringer Mannheim Gmbh Monoklonale antikoerper gegen melanom
DE69124683T2 (de) * 1990-11-30 1997-09-11 Kyowa Hakko Kogyo Kk Monoklonale Antikörper gegen Glykolipid-Karbohydratketten

Also Published As

Publication number Publication date
KR930019820A (ko) 1993-10-19
EP0561183B1 (de) 1998-08-19
US5730981A (en) 1998-03-24
AU3531893A (en) 1993-09-23
CA2091967C (en) 2006-11-07
ATE169962T1 (de) 1998-09-15
ES2121881T3 (es) 1998-12-16
JPH0646882A (ja) 1994-02-22
JP3513173B2 (ja) 2004-03-31
EP0561183A1 (de) 1993-09-22
DE4208795A1 (de) 1993-09-23
KR100280948B1 (ko) 2001-04-02
NO930990L (no) 1993-09-20
NO315089B1 (no) 2003-07-07
IL105081A (en) 1998-01-04
NO930990D0 (no) 1993-03-18
DE59308875D1 (de) 1998-09-24
AU666707B2 (en) 1996-02-22
CA2091967A1 (en) 1993-09-20
IL105081A0 (en) 1993-07-08

Similar Documents

Publication Publication Date Title
NO910923D0 (no) Trifunksjonell antistofflignende forbindelse som et kombinert diagnostisk og terapeutisk middel.
EP0597829A4 (en) NEW MONOCLONAL ANTIBODY DRESSES AGAINST A NEW ANTIGEN ASSOCIATED WITH HUMAN TUMORS.
BR8907507A (pt) Quelante bifuncional macrociclico,seus complexos e seus conjugados com anticorpos
NO20002957D0 (no) Behandling med anti-ErbB2-antistoffer
BR9206313A (pt) Anticorpos recombinantes para terapia humana.
AR035977A1 (es) Inmunoconjugados de anticuerpos cd44 citotoxicos.
DE3783277D1 (de) Monoklonaler antikoerper gegen humanes lungenkarzinom.
DE3574730D1 (de) Monoklonaler antikoerper gegen ein humanes tumor-karzinom-assoziiertes antigen.
ATE267610T1 (de) Glykosylierte igg antikörper
GB9824632D0 (en) Biological compounds
GB2185266B (en) Monoclonal antibodies cross-reactive and cross-protective against p. aeruginosa serotypes
NO910922D0 (no) Tris-maleimidoforbindelser som mellomprodukter i trifunksjonell antistoffsyntese.
IT8341601A0 (it) Dispositivo di apertura delle ante scorrevoli allineate di mobili.
DK556689D0 (da) Antistof-konjugater, fremgangsmaade til fremstilling heraf og farmaceutiske midler indeholdende disse
DE3885355D1 (de) Monoklonale Antikörper.
DE3682250D1 (de) Einen monoklonalen antikoerper gegen kupfer-zink-superoxiddismutase enthaltendes arzneimittel fuer diagnostischen test und dasselbe verwendendes diagnostisches testverfahren.
DK0561183T3 (da) Monoklonalt anti-gangliosid-antistof, fremstilling deraf og anvendelse deraf som tumorterapeutikum
TR200103432T2 (tr) Engelleyici monoklonal VLA-1 antikoru ve enflamasyonlu hastalıkların tedavisinde kullanımı.
DE68908426T2 (de) Adjuvanz für Krebsimmuntherapie.
DK169987D0 (da) Human tumor-associated antigen, ca-ou1
NO894444L (no) Anti-fucosylceramid monoklonalt antistoff.
DE3485965T2 (de) Monoklonaler antikoerper mit spezifitaet gegen nur einen typ eines isozyms der schweren kette des menschlichen herzmyosins.
DE3785795D1 (de) Monoklonale anti-menschliche magenkrebs-antikoerper.
NO894555D0 (no) Monoklonalt antistoff som spesifikt gjenkjenner n-glycolyl type gm2, hybridom som produserer antistoff og fremgangsmaate for fremstilling av hybridomet.
MX9202642A (es) Anticuerpos monoclonales y antigeno para melanoma humano.